OncoTalks | Oncology Insights at Your Fingertips

In this episode of OncoTalks, host Tulsi Patel speaks with Dr. Hope Rugo about the evolving role of antibody‑drug conjugates (ADCs) in breast cancer, with a focus on sacituzumab govitecan, the first and currently only approved ADC for patients with previously treated metastatic triple‑negative breast cancer (mTNBC). Dr. Rugo highlights key clinical data supporting its approvals in mTNBC and HR‑positive/HER2‑negative disease, and di...

In this episode of OncoTalks, host Dr. Ira Zackon is joined by Dr. Alexander Spira to discuss comprehensive biomarker testing in non-small cell lung cancer (NSCLC). They unpack key findings from a recent study revealing variability in testing practices and emphasize the importance of comprehensive DNA- and RNA-based next-generation sequencing over single-gene testing. Tune in to review the latest clinical guidelines, learn how test...

In this episode of OncoTalks, Dr. Paul Conkling and Dr. Eric Nadler take a deep dive into the IMforte trial—a pivotal phase III global study evaluating lurbinectedin and atezolizumab as a first-line maintenance therapy for extensive-stage small-cell lung cancer (ES-SCLC). They unpack the trial’s design and results, highlighting key safety and efficacy data that led to the FDA’s approval of this combination regimen on October 2, 202...

In this episode, Dr. Paul Conkling and Dr. David Spetzler explore the advantages of broad molecular profiling over smaller panels, emphasizing its superior accuracy in detecting critical biomarkers and identifying eligibility for emerging therapies. They discuss how AI is transforming treatment sequencing and improving patient outcomes, while also highlighting key technical factors—such as microdissection and advanced extraction me...

In this episode of OncoTalks, Dr. Paul Conkling and Dr. Kashif Ali explore how minimal residual disease (MRD) testing using circulating tumor DNA (ctDNA) is reshaping breast cancer management. They discuss how this innovative approach enables the detection of molecular disease that may persist after treatment — often before clinical or radiographic signs appear. Research shows MRD testing can identify recurrence months earlier than...

In this episode of OncoTalks, Dr. Mia Levy and Dr. Paul Conkling discuss new FDA-approved treatments and therapies for HR-positive, HER2-negative metastatic breast cancer. Discover innovative genomic testing techniques that are changing the identification of mutations, paving the way for more precise treatment strategies. Tune in as we spotlight advancements in personalized breast cancer care and learn about the advantages of liqui...

In this episode of OncoTalks, Dr. Paul Conkling and Dr. David Cosgrove explore the latest advancements in mCRC treatment, highlighting the shift from traditional chemotherapy to innovative targeted therapies driven by genomic insights. We discuss the role of next-generation sequencing, new therapeutic agents, and clinical trials, while emphasizing personalized care, addressing treatment challenges, side effects, and financial consi...

Join us for the conclusion of our 2-part series on HER2-low breast cancer, featuring Dr. Paul Conkling and Dr. Erika Hamilton. They discuss the Phase 1 results from a HER2-low retrospective study evaluating HER2 testing patterns and concordant therapy in patients with HER2 metastatic breast cancer. Learn about the evolving role of HER2-low classification, ongoing education, and treatment strategies to enhance patient outcomes.

Deve...

Join us as we explore the transformative potential of HER2 testing in breast cancer care. In this episode of OncoTalks, Dr. Paul Conkling and Dr. Erika Hamilton share cutting-edge insights that every oncologist should know to stay at the forefront of breast cancer treatment. Tune in to discover how HER2 testing is reshaping the landscape of personalized cancer therapy.

Developed and produced by Ontada Learn. The content is intended...

Join Dr. Robert Reid and Dr. Sreeni Chittoor as they explore the revolutionary impact of genomic testing in redefining cancer treatment. We focus on advanced solid tumors, such as non-small cell lung cancer (NSCLC), breast cancer, and colorectal cancer, examining how these state-of-the-art technologies are leading to more personalized and effective treatment strategies.

Developed and produced by Ontada Learn. The content is intende...

In this episode of OncoTalks, Dr. David Waterhouse and Dr. Paul Conkling discuss NSCLC and the groundbreaking developments in treating patients with MET exon 14 (METex14) skipping mutations. We review the science behind these targeted therapies, their clinical applications, and the impact on patient outcomes.

Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and e...

In this episode, Dr. David Waterhouse and Dr. Paul Conkling discuss the evolving landscape of second line treatments for extensive stage small cell lung cancer (SCLC). They review the latest research, promising therapies, and the impact of these treatments on patient quality of life. This episode offers vital information to help navigate treatment options and empower patients. Don’t miss this engaging discussion on a crucial topic ...